

Title (en)
METHOD FOR USING POTASSIUM CHANNEL ACTIVATION FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR

Title (de)
VERWENDUNG VON KALIUMKANALAKTIVATOREN ZUR VERABREICHUNG VON MEDIKAMENTEN AN ANORMALEN GEHIRNREGIONEN UND/ODER BÖSARTIGEN TUMOREN

Title (fr)
PROCEDE UTILISANT L'ACTIVATION DES CANAUX POTASSIQUES POUR L'APPORT D'UN MEDICAMENT JUSQU'A UNE REGION ANORMALE DU CERVEAU ET/OU JUSQU'A UNE TUMEUR MALIGNE

Publication
EP 1251840 A2 20021030 (EN)

Application
EP 01905141 A 20010126

Priority
• US 0102742 W 20010126
• US 49150000 A 20000126
• US 61585400 A 20000714

Abstract (en)
[origin: WO0154771A2] Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a calcium- or ATP-dependent potassium channel [KCa or KATP] activator (other than bradykinin or a bradykinin analog), such as a direct potassium channel agonist or an indirect potassium channel activator, such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.

IPC 1-7
A61K 31/047; **A61K 31/21**; **A61K 31/4245**; **A61K 31/708**; **A61P 35/00**

IPC 8 full level
A61K 45/00 (2006.01); **A61K 31/00** (2006.01); **A61K 31/04** (2006.01); **A61K 31/198** (2006.01); **A61K 31/21** (2006.01); **A61K 31/282** (2006.01); **A61K 31/295** (2006.01); **A61K 31/401** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/4245** (2006.01); **A61K 31/43** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4409** (2006.01); **A61K 31/475** (2006.01); **A61K 31/495** (2006.01); **A61K 31/506** (2006.01); **A61K 31/513** (2006.01); **A61K 31/519** (2006.01); **A61K 31/655** (2006.01); **A61K 31/675** (2006.01); **A61K 31/69** (2006.01); **A61K 33/00** (2006.01); **A61K 33/04** (2006.01); **A61K 33/26** (2006.01); **A61K 38/00** (2006.01); **A61K 45/06** (2006.01); **A61K 45/08** (2006.01); **A61K 49/00** (2006.01); **A61K 49/04** (2006.01); **A61K 51/12** (2006.01); **A61P 25/00** (2006.01); **A61P 31/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C12N 15/88** (2006.01)

CPC (source: EP)
A61K 31/00 (2013.01); **A61K 31/04** (2013.01); **A61K 31/198** (2013.01); **A61K 31/21** (2013.01); **A61K 31/282** (2013.01); **A61K 31/295** (2013.01); **A61K 31/4245** (2013.01); **A61K 31/44** (2013.01); **A61K 31/475** (2013.01); **A61K 31/513** (2013.01); **A61K 31/519** (2013.01); **A61K 31/655** (2013.01); **A61K 31/675** (2013.01); **A61K 31/69** (2013.01); **A61K 33/00** (2013.01); **A61K 45/06** (2013.01); **A61P 25/00** (2017.12); **A61P 31/00** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C12N 15/88** (2013.01)

Citation (search report)
See references of WO 0154680A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0154771 A2 20010802; **WO 0154771 A3 20020620**; AU 3305201 A 20010807; AU 3460201 A 20010807; EP 1251840 A2 20021030; JP 2003523965 A 20030812; JP 2004508279 A 20040318; WO 0154680 A2 20010802; WO 0154680 A3 20020627

DOCDB simple family (application)
US 0102743 W 20010126; AU 3305201 A 20010126; AU 3460201 A 20010126; EP 01905141 A 20010126; JP 2001554753 A 20010126; JP 2001555658 A 20010126; US 0102742 W 20010126